Ebastine

Summary

Ebastine (CHEMBL305660) is an approved small molecule (ATC R06AX22); indicated across 2 conditions including allergic disease and irritable bowel syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AX22
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 469.7 Da · C32H39NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL305660
Name	Ebastine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3191
ATC	R06AX22
Molecular formula	C32H39NO2
Molecular weight	469.7
InChIKey	MJJALKDDGIKVBE-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4

IUPAC name: 4-(4-benzhydryloxypiperidin-1-yl)-1-(4-tert-butylphenyl)butan-1-one

Also known as: Ebastina, Ebastine, LAS W-090, LAS-W-090, RP 64305, RP-64305, SID26758025, SID90340626, EBASTINE, SID144205778, SID170465995, ebastine

Patent coverage: 2,689 distinct patent families (10,024 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 54 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, NPC intracellular cholesterol transporter 1, Ras-related protein Rab-9A, Muscarinic acetylcholine receptor M4, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor.

Bioactivity

ChEMBL activities: 87 potent at pChembl ≥ 5 of 103 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	8.48	Ki	3.29	nM	CHEMBL_ACT_7647745
HTR2A	7.59	Ki	25.8	nM	CHEMBL_ACT_7649845
PRKAA2	7.58	Ki	26	nM	CHEMBL_ACT_25872880
HRH1	7.55	IC50	28.3	nM	CHEMBL_ACT_7647744
ADRA2C	7.4	Ki	40.1	nM	CHEMBL_ACT_7647647
DRD3	7.38	Ki	41.3	nM	CHEMBL_ACT_7647715
P31389	7.35	IC50	45	nM	CHEMBL_ACT_576827
HTR1A	7.33	IC50	47	nM	CHEMBL_ACT_576831
DRD2	7.21	IC50	61	nM	CHEMBL_ACT_576832
SLC6A3	7.11	Ki	78.4	nM	CHEMBL_ACT_7647719
KCNH2	7.07	Ki	85.8	nM	CHEMBL_ACT_7649803
HTR2A	7.04	IC50	90.4	nM	CHEMBL_ACT_7649844
SLC6A3	7.01	IC50	98.7	nM	CHEMBL_ACT_7647718
CHRM1	7	Ki	101.2	nM	CHEMBL_ACT_7647773
KCNH2	6.98	IC50	104.8	nM	CHEMBL_ACT_7649802
CHRM4	6.94	Ki	115.5	nM	CHEMBL_ACT_7647779
DRD3	6.92	IC50	121.6	nM	CHEMBL_ACT_7647714
HTR2C	6.91	Ki	124.4	nM	CHEMBL_ACT_7649849
CHRM3	6.86	Ki	137.2	nM	CHEMBL_ACT_7647777
MLNR	6.8	AC50	160	nM	CHEMBL_ACT_25189046
ADRA1D	6.74	IC50	183	nM	CHEMBL_ACT_576828
HTR2B	6.7	Ki	198.9	nM	CHEMBL_ACT_7649847
P15823	6.63	Ki	232.9	nM	CHEMBL_ACT_7647639
CHRM5	6.62	Ki	242.7	nM	CHEMBL_ACT_7649771
HTR2C	6.62	IC50	237.5	nM	CHEMBL_ACT_7649848
ADRA2C	6.56	IC50	275.7	nM	CHEMBL_ACT_7647646
CHRM2	6.55	Ki	279.5	nM	CHEMBL_ACT_7647775
ADRA2A	6.51	Ki	311.9	nM	CHEMBL_ACT_7647643
HTR2B	6.5	IC50	312.6	nM	CHEMBL_ACT_7649846
KCNH2	6.48	IC50	331.1	nM	CHEMBL_ACT_5218942

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01144832	PHASE4	COMPLETED	Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
NCT01908465	PHASE4	COMPLETED	Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
NCT01940393	PHASE4	COMPLETED	Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
NCT05815602	PHASE3	RECRUITING	Ebastine Versus Mebeverine in IBS Patients
NCT07114055	PHASE2/PHASE3	RECRUITING	Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
NCT06480110	PHASE1/PHASE2	RECRUITING	Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).